Regression of Uveal Metastases Following Treatment with PARP-Inhibitor in a Patient with Germline BRCA Mutation and Advanced Breast Cancer

Lona Jawaheer, Vikas Chadha and Paul Cauchi

Tennent Institute of Ophthalmology, Gartnavel General Hospital, UK

^*Correspondance to: Lona Jawaheer 

 PDF  Full Text Case Report | Open Access

Abstract:

Uveal metastases from breast, lung or gastrointestinal malignancies represent the most frequent intraocular malignancy. We present a case of a 52-year old female patient with metastatic breast cancer with lung and liver involvement, known to be a BRCA2 mutation carrier. Following a presentation to the emergency service with pain and blurred vision in her left eye, she was diagnosed with uveal metastases. Ten days following this new diagnosis, she was enrolled onto a clinical trial of olaparib, a PARP-inhibitor (Phase 1 Food Effect Study D081ACC00001, NCT01851265). She subsequently developed an improvement in her vision (Snellen visual acuity increased from 1/60 to 6/18 over 6 weeks) and the ocular tumour with its associated retinal detachment was noted to have regressed considerably. PARP inhibitors are currently involved in several clinical trials for ovarian/breast cancers associated with BRCA mutations. They work by preferentially targeting DNA repair defects in BRCA-positive mutated cancer cells. In this case olaparib caused regression of ocular metastases in a patient with a BRCA mutation and advanced breast cancer. It supports the case for further research towards offering targeted treatment through gene expression analyses and biomarker functional assays.

Keywords:

Cite the Article:

Jawaheer L, Chadha V, Cauchi P. Regression of Uveal Metastases Following Treatment with PARPInhibitor in a Patient with Germline BRCA Mutation and Advanced Breast Cancer. Ann Clin Case Rep. 2019; 4: 1596.